RetroVirox is a privately-held company. In 2008, RetroVirox raised seed-funds to cover initial operations and since inception has secured over $5 million dollars in non-dilutive funds from the Small Business innovation and Research program (SBIR) of the National Institutes of Health (NIH). Our initial investors included entrepreneurs and renowned scientists from the academic and biotechnology fields, with decades of experience in antivirals, assay development, and high-throughput screening assays.

RetroVirox is focusing its R&D efforts in two programs currently at the advanced lead series optimization. The most advanced project is the development of small-molecule immunomodulators for HIV eradication. Novel chemical entities with activity in the low nM range have been identified and the company is now seeking partnership opportunities and venture capital financing to advance the HIV immunomodulatory program and characterize preclinical candidates for human trials. The company has developed small molecules with broad anti-cancer activity and is currently assessing their activity in small animal models of melanoma, leukemia and lymphoma.

Partnerships and Collaborations

RetroVirox is interested in working with companies to: i) expand the size of our medicinal chemistry and preclinical biology efforts with the HIV and Cancer programs. 

The company is also discussing alternative mechanisms for partnerships and collaborations. RetroVirox has helped other small companies with joint grant applications to finance early-stage research and preclinical development of their novel anti-viral targets

For additional information regarding investments, collaborations and partnership opportunities with RetroVirox please contact us.